Study highlights glycolysis as a potential therapeutic target to combat Mycobacterium tuberculosis

It has been uncertain how Mycobacterium tuberculosis deflects the immune response in humans, though evidence has pointed to host immunometabolism -; the intrinsic link between metabolism in immune cells and their immune function.

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

The therapy is a once-weekly SC injection. Credit: Chinnapong via Shutterstock. Zai Lab and Argenx have announced receipt of approval from the National Medical Products Administration

November 12, 2024

Novel lipid nanoparticles enhance tissue-specific drug delivery

Penn Engineers have discovered a novel means of directing lipid nanoparticles (LNPs), the revolutionary molecules that delivered the COVID-19 vaccines, to target specific tissues, presaging

October 1, 2024

Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey there. So, today

January 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.